NEUP · Neuphoria Therapeutics Inc.
Market Cap
$20.32M
Shares
5.40M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.76
Open$3.71
Day$3.71–3.82
52W close$3.30–20.00
Avg vol 30d323K
Short int42K · 0.8% float · 1.5d
Short vol7%
DataDec 2024–Aug 2026
Filing10-Q · May 15
Raw chart and full-history price indicators begin at the captured split on Dec 24, 2024; bars on opposite sides are not compared.
Up next
FQ1-27 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.70
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−13%
below
Price vs 50-day avg
−2%
below
RSI (14)
44
neutral
MACD trend
Negative
52-week position
3%
near low
Momentum
relative strength
1-month return
−4%
trailing
6-month return
−19%
trailing
YTD return
−3%
this year
Relative strength
−32%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
+16% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.78% of float · ▼ -35.9% MoM · 1.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
22 holders — near 1-yr high, broad support
Squeeze score
34
low risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
121%
annualized · 1-yr
Max drawdown
−84%
past year
ATR
4.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−13%
Bearish
Price vs 50-day avg
−2%
Neutral
RSI (14)
44
Neutral
MACD trend
Negative
Bearish
52-week position
3%
Bearish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
+16% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.78% of float · ▼ -35.9% MoM · 1.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
22 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $3
Now $4 · 3%
Range high $20
vs 200-day avg -13%
vs 50-day avg -2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NEUP
this stock
Neuphoria Therapeutics Inc.
|
$20.32M | -3.1% | — | — | 0.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +20.1% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.77B | +3.5% | +20.8% | 19.7 | 2.3% |
|
ARGX
Argenx SE
|
$64.16B | +22.7% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.51B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
Raw-price comparisons begin at the captured split on Dec 24, 2024; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NEUP | -4.8% | -4.3% | -19.1% | -3.1% | -3.1% |
| SPY | +0.5% | +1.2% | +13.3% | +2.7% | +12.5% |
| vs SPY | -5.3% | -5.6% | -32.4% | -5.8% | -15.6% |
Key facts
CIK
1191070
CUSIP
64136E102
13F (30d)
20 filings
20 filers
Visit website
Investor relations